What is the recommended dose of posaconazole in an adult patient?

Posaconazole Dosing in Adults

For prophylaxis of invasive fungal infections, administer posaconazole delayed-release tablets 300 mg twice daily on day 1, then 300 mg once daily starting day 2; for treatment of invasive fungal infections, use 300 mg twice daily on day 1, then 300 mg once daily, or consider higher doses (400 mg daily) for optimal therapeutic efficacy. 1

Dosing by Formulation

The dose of posaconazole varies significantly by formulation, and these formulations are NOT interchangeable 2:

Delayed-Release Tablets (Preferred Formulation)

• Prophylaxis: 300 mg twice daily on day 1 (loading), then 300 mg once daily 1
• Treatment: 300 mg twice daily on day 1 (loading), then 300 mg once daily 3
• Can be taken with or without food 1
• Swallow whole; do not crush, divide, or chew 1

Intravenous Solution

• Loading: 300 mg IV twice daily on day 1
• Maintenance: 300 mg IV once daily 2
• Preferred route when oral administration is not feasible 3

Oral Suspension (Less Preferred)

• Initial dosing: 200 mg (5 mL) four times daily
• After stabilization: 400 mg (10 mL) twice daily 2
• Must be taken with fatty food for optimal absorption 2
• This formulation has unpredictable bioavailability and is generally avoided when tablets or IV are available 4

Clinical Context-Specific Dosing

For Mucormycosis (COVID-Associated or Otherwise)

• Primary therapy alternative: 300 mg IV or PO twice daily on day 1, then 300 mg once daily 3
• Maintenance therapy: 300 mg IV or PO twice daily on day 1, then 300 mg once daily for 3-6 months 3
• IV formulation preferred over oral 3

For Invasive Aspergillosis

The 2023 Taiwan guidelines and 2019 global mucormycosis guidelines consistently recommend the same dosing as above 2, 3, 2. However, recent pharmacokinetic/pharmacodynamic modeling suggests that standard dosing may be insufficient for treatment 5. For treatment of aspergillosis (not prophylaxis), consider:

• Higher-dose regimen: 200 mg every 12 hours (delayed-release tablets) to achieve optimal therapeutic efficacy 5
• Standard 300 mg daily may only be adequate for prophylaxis or treatment of highly susceptible organisms (MIC ≤0.125 µg/mL) 5

Critical Considerations

Therapeutic Drug Monitoring (TDM)

TDM is strongly recommended for all patients receiving posaconazole for treatment, regardless of formulation 6. Despite manufacturer claims that delayed-release tablets achieve predictable levels:

• 47.9% of patients had initial steady-state troughs <1.3 mg/L 6
• 28.8% had troughs <1.0 mg/L 6

Target concentrations:

• Prophylaxis: ≥0.7 mg/L 7, 8
• Treatment: ≥1.0 mg/L (some experts recommend ≥1.3 mg/L) 7, 8, 6

Factors Reducing Posaconazole Levels

Monitor closely and consider dose adjustment in patients with:

• Body weight ≥90 kg or BMI ≥30 kg/m² 6
• Acid suppressive therapy (proton pump inhibitors, H2 blockers) 9
• Severe diarrhea or vomiting 1
• Concomitant corticosteroids (methylprednisolone ≥0.7 mg/kg/day) 9

Dose Adjustments Based on TDM

If trough concentrations are subtherapeutic with delayed-release tablets 6, 10:

• Consider increasing to 400 mg once daily for maintenance
• For oral suspension: increase frequency to 200 mg four times daily or dose to 300 mg three times daily 10
• Initial doses higher than 300 mg daily should be strongly considered for patients with risk factors 6

Special Populations

• Renal impairment: No dose adjustment needed for oral formulations 1
• Hepatic impairment: No specific dose adjustment recommended, but monitor closely
• Critically ill patients: Consider loading regimen of 300 mg q12h and 300 mg q8h in first two days for patients <100 kg and ≥100 kg respectively, then 400 mg daily maintenance 11

Duration of Therapy

• Prophylaxis: Continue until recovery from neutropenia or immunosuppression 1
• Treatment: Minimum 4-6 weeks for induction/consolidation, then 3-6 months maintenance until resolution of clinical signs and symptoms 3

Common Pitfalls

1. Assuming formulations are interchangeable - they are not; dosing differs significantly
2. Not performing TDM for treatment - even with delayed-release tablets, nearly half of patients have subtherapeutic levels
3. Using standard 300 mg daily for treatment - may be insufficient; consider 400 mg daily or higher based on TDM
4. Ignoring drug interactions - particularly with acid suppressants, which significantly reduce absorption